Anew Medical, Inc. specializes in developing disease-modifying therapies for age-related cognitive and neurodegenerative disorders, as well as cancer.
Anew Medical, Inc. is at the forefront of developing transformative therapies aimed at age-related cognitive and neurodegenerative disorders, as well as cancer. Our pioneering approach integrates cutting-edge cell and gene therapies to develop disruptive treatments designed to halt or even reverse the progression of devastating illnesses like Alzheimer's disease and various cancers. By leveraging innovative scientific methodologies, we strive to deliver therapies that promise profound and enduring therapeutic benefits.
Central to our innovation strategy are two key platform technologies licensed exclusively by Anew Medical, Inc. These include biosimilar biologics targeting cancer, particularly biosimilars of Roche/Genentech's bevacizumab (Avastin) and rituximab (Mabthera and Rituxan), known for their efficacy in the market. Additionally, we have licensed groundbreaking gene therapy technology utilizing the a-Klotho gene, aiming to utilize a novel truncated protein (s+KL) that mimics the functions of the full-length soluble a-Klotho protein (s-KL) and shares properties with the transmembrane-bound a-Klotho protein (m-KL). This technology holds promise for anti-aging treatments and combating neurodegenerative diseases.
Founded on a commitment to advancing medical science, Anew Medical, Inc. collaborates closely with corporate partners to bring blockbuster biologic drugs to market. Our focus extends to commercializing therapies that have already demonstrated their efficacy and similarity to established reference antibodies. By pioneering these groundbreaking therapies, we aim to redefine treatment paradigms and significantly improve outcomes for patients worldwide.